EZH2 and diffuse large B-cell lymphoma: GSK126, one of the first selective EZH2 inhibitors, was extensively tested in DLBCL lymphoma cell lines leading to significant growth inhibition and increased apoptotic rate with maximal potency after 2 days [41].